Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin plus bortezomib, lenalidomide, dexamethasone versus bortezomib, lenalidomide, dexamethasone in transplant-ineligible newly diagnosed multiple myeloma (Phase 3)
2019-003047-30Phase 3Active
- Sponsor
- GSK
- Start
- Sep 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Belantamab mafodotin combination arm with Standard-of-care arm (2 arms). Primary endpoint: Primary endpoint (Part 1). Started Sep 2019; status: active.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-003047-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003047-30.